Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment
Small · 28.03.2023
DOI: 10.1002/smll.202300666 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, online erschienen am 28.03.2023. Verfasst von Sofia Torres Quintas und 4 weiteren Autor:innen. Beteiligte Einrichtung: i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Nanomedicine, Women's Health. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Portuguese Science and Technology Foundation, European Regional Development Fund, Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
Breast cancer appears as the major cause of cancer‐related deaths in women, with more than 2 260 000 cases reported worldwide in 2020, resulting in 684 996 deaths. Triple‐negative breast cancer (TNBC), characterized by the absence of estrogen, progesterone, and human epidermal growth factor type 2 receptors, represents ≈20% of all breast cancers. TNBC has a highly aggressive clinical course and is more prevalent in younger women. The standard therapy for advanced TNBC is chemotherapy, but responses are often short‐lived, with high rate of relapse. The lack of therapeutic targets and the limited therapeutic options confer to individuals suffering from TNBC the poorest prognosis among breast cancer patients, remaining a major clinical challenge. In recent years, advances in cancer nanomedicine provided innovative therapeutic options, as nanoformulations play an important role in overcoming the shortcomings left by conventional therapies: payload degradation and its low solubility, stability, and circulating half‐life, and difficulties regarding biodistribution due to physiological and biological barriers. In this integrative review, the recent advances in the nanomedicine field for TNBC treatment, including the novel nanoparticle‐, exosome‐, and hybrid‐based therapeutic formulations are summarized and their drawbacks and challenges are discussed for future clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
- INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Rua Alfredo Allen 208, Porto, 4200-135, Portugal.
- ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Rua Jorge de Viterbo Ferreira 228, Porto, 4050-313, Portugal.
- IUCS-CESPU - Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra 1317, 4585-116, Gandra, Portugal.
ORCID-Profile: Bruno Sarmento
Förderung
- Portuguese Science and Technology Foundation
- European Regional Development Fund
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Torres Quintas, S., Canha-Borges, A., Oliveira, M. J., Sarmento, B., & Castro, F. (2023). Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment. Small. https://doi.org/10.1002/smll.202300666
Vancouver
Torres Quintas S, Canha-Borges A, Oliveira MJ, Sarmento B, Castro F. Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment. Small. 2023. doi:10.1002/smll.202300666
BibTeX
@article{TorresQuintas2023,
author = {Torres Quintas, Sofia and Canha-Borges, Ana and Oliveira, Maria José and Sarmento, Bruno and Castro, Flávia},
title = {Special Issue: Nanotherapeutics in Women's Health Emerging Nanotechnologies for Triple‐Negative Breast Cancer Treatment},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202300666}
}
EUVIMED